Published in Nat Med on December 16, 2007
A Crossover Pilot Study of the Effect of Amiloride on Proteinuria | NCT02522650
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med (2015) 4.85
AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med (2013) 3.41
Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice. J Am Soc Nephrol (2014) 2.91
Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol (2008) 2.71
Cell biology and pathology of podocytes. Annu Rev Physiol (2011) 2.42
Proteinuria: an enzymatic disease of the podocyte? Kidney Int (2009) 2.17
The podocyte cytoskeleton--key to a functioning glomerulus in health and disease. Nat Rev Nephrol (2011) 1.86
Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol (2012) 1.83
CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance. Pediatr Nephrol (2013) 1.83
New insights into the role of podocytes in proteinuria. Nat Rev Nephrol (2009) 1.77
Participation of the urokinase receptor in neutrophil efferocytosis. Blood (2009) 1.62
Peptide nanofibers preconditioned with stem cell secretome are renoprotective. J Am Soc Nephrol (2011) 1.57
TNFα pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β3 integrin activation. Pediatr Nephrol (2012) 1.57
CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. J Clin Invest (2011) 1.49
Inhibition of podocyte FAK protects against proteinuria and foot process effacement. J Am Soc Nephrol (2010) 1.44
Neph-Nephrin proteins bind the Par3-Par6-atypical protein kinase C (aPKC) complex to regulate podocyte cell polarity. J Biol Chem (2008) 1.43
uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180. J Cell Biol (2008) 1.43
A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med (2014) 1.39
A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease. Kidney Int (2014) 1.33
The role of osteopontin in the development of albuminuria. J Am Soc Nephrol (2008) 1.33
Podocyte biology and pathogenesis of kidney disease. Annu Rev Med (2012) 1.32
Divergent functions of the Rho GTPases Rac1 and Cdc42 in podocyte injury. Kidney Int (2013) 1.27
Periostin is induced in glomerular injury and expressed de novo in interstitial renal fibrosis. Am J Pathol (2011) 1.19
Abnormalities in signaling pathways in diabetic nephropathy. Expert Rev Endocrinol Metab (2010) 1.19
New insights into human minimal change disease: lessons from animal models. Am J Kidney Dis (2011) 1.18
New developments in steroid-resistant nephrotic syndrome. Pediatr Nephrol (2012) 1.18
Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. Blood (2011) 1.17
Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. J Biol Chem (2010) 1.14
Serum suPAR in patients with FSGS: trash or treasure? Pediatr Nephrol (2013) 1.13
Recent progress in the pathophysiology and treatment of FSGS recurrence. Am J Transplant (2013) 1.13
Mutations in the gene that encodes the F-actin binding protein anillin cause FSGS. J Am Soc Nephrol (2014) 1.12
Serine proteases, inhibitors and receptors in renal fibrosis. Thromb Haemost (2009) 1.10
Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. J Am Soc Nephrol (2014) 1.09
Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins. J Cell Sci (2008) 1.08
Acute podocyte vascular endothelial growth factor (VEGF-A) knockdown disrupts alphaVbeta3 integrin signaling in the glomerulus. PLoS One (2012) 1.05
Toward the development of podocyte-specific drugs. Kidney Int (2010) 1.04
A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR). J Biol Chem (2012) 1.03
Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor. Mol Biol Cell (2008) 1.03
Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. Pediatr Nephrol (2014) 1.02
Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease. Nat Med (2016) 1.02
The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury. J Mol Med (Berl) (2012) 1.02
Cell-matrix adhesion of podocytes in physiology and disease. Nat Rev Nephrol (2013) 1.02
ARHGDIA: a novel gene implicated in nephrotic syndrome. J Med Genet (2013) 1.01
Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol (2013) 1.01
Role of urokinase receptor in tumor progression and development. Theranostics (2013) 1.00
Dystroglycan does not contribute significantly to kidney development or function, in health or after injury. Am J Physiol Renal Physiol (2011) 1.00
Lipid biology of the podocyte--new perspectives offer new opportunities. Nat Rev Nephrol (2014) 0.99
A Podocyte-Based Automated Screening Assay Identifies Protective Small Molecules. J Am Soc Nephrol (2015) 0.99
Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis. BMC Med (2014) 0.98
Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients. Br J Cancer (2010) 0.98
Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS. Clin J Am Soc Nephrol (2014) 0.96
Pathogenic old world hantaviruses infect renal glomerular and tubular cells and induce disassembling of cell-to-cell contacts. J Virol (2011) 0.96
Loss of beta1-integrin enhances TGF-beta1-induced collagen expression in epithelial cells via increased alphavbeta3-integrin and Rac1 activity. J Biol Chem (2010) 0.95
Integrins in kidney disease. J Am Soc Nephrol (2013) 0.95
Blocking ligand occupancy of the αVβ3 integrin inhibits the development of nephropathy in diabetic pigs. Endocrinology (2014) 0.94
Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor. J Biol Chem (2011) 0.94
Therapeutic targets in focal and segmental glomerulosclerosis. Curr Opin Nephrol Hypertens (2008) 0.94
Urokinase and its receptors in chronic kidney disease. Front Biosci (2008) 0.94
Podocyte biology for the bedside. Am J Kidney Dis (2011) 0.94
MMP-9, uPAR and cathepsin B silencing downregulate integrins in human glioma xenograft cells in vitro and in vivo in nude mice. PLoS One (2010) 0.93
Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes. Sci Rep (2015) 0.93
Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor. World J Nephrol (2013) 0.92
Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated β1-integrin endocytosis. Am J Physiol Renal Physiol (2015) 0.92
The pathogenesis of focal segmental glomerulosclerosis. Adv Chronic Kidney Dis (2014) 0.92
Amiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR. Case Rep Nephrol (2014) 0.91
Blocking αVβ3 integrin ligand occupancy inhibits the progression of albuminuria in diabetic rats. J Diabetes Res (2014) 0.91
Rituximab treatment prevents the early development of proteinuria following pig-to-baboon xeno-kidney transplantation. J Am Soc Nephrol (2014) 0.90
Urokinase receptor mediates lung fibroblast attachment and migration toward provisional matrix proteins through interaction with multiple integrins. Am J Physiol Lung Cell Mol Physiol (2009) 0.90
The importance of podocyte adhesion for a healthy glomerulus. Front Endocrinol (Lausanne) (2014) 0.89
Experimental concerns regarding suPAR-related proteinuria. Nat Rev Nephrol (2017) 0.89
Glomerular proteinuria: a complex interplay between unique players. Adv Chronic Kidney Dis (2011) 0.89
Podocyturia: What is in a name? J Transl Int Med (2015) 0.88
Biomarkers of kidney injury and klotho in patients with atherosclerotic renovascular disease. Clin J Am Soc Nephrol (2014) 0.87
Podocyte pathology and nephropathy - sphingolipids in glomerular diseases. Front Endocrinol (Lausanne) (2014) 0.87
The glomerular filtration barrier: components and crosstalk. Int J Nephrol (2012) 0.87
Is there clinical value in measuring suPAR levels in FSGS? Clin J Am Soc Nephrol (2013) 0.87
Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View. J Immunol Res (2016) 0.87
The glomerular permeability factors in idiopathic nephrotic syndrome. Pediatr Nephrol (2015) 0.86
MicroRNA-30 family members regulate calcium/calcineurin signaling in podocytes. J Clin Invest (2015) 0.86
LPS nephropathy in mice is ameliorated by IL-2 independently of regulatory T cells activity. PLoS One (2014) 0.85
Role of integrins in regulating proteases to mediate extracellular matrix remodeling. Cancer Microenviron (2012) 0.85
The Gne M712T mouse as a model for human glomerulopathy. Am J Pathol (2012) 0.85
A deficiency of uPAR alters endothelial angiogenic function and cell morphology. Vasc Cell (2011) 0.84
Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus. Sci Rep (2017) 0.84
A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes. Exp Physiol (2014) 0.83
NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice. Br J Pharmacol (2013) 0.83
Receptor activator of NF-kappaB and podocytes: towards a function of a novel receptor-ligand pair in the survival response of podocyte injury. PLoS One (2012) 0.82
Urokinase plasminogen activator receptor (uPAR) targeted nuclear imaging and radionuclide therapy. Theranostics (2013) 0.82
In vivo electroporation and non-protein based screening assays to identify antibodies against native protein conformations. Hybridoma (Larchmt) (2011) 0.82
Establishment of protein delivery systems targeting podocytes. PLoS One (2010) 0.82
Proteomic analysis identifies insulin-like growth factor-binding protein-related protein-1 as a podocyte product. Am J Physiol Renal Physiol (2010) 0.82
Role of the AP-1 transcription factor FOSL1 in endothelial cells adhesion and migration. Cell Adh Migr (2013) 0.82
Filtering new facts about kidney disease. Nat Med (2011) 0.82
Circulating Permeability Factors in Primary Focal Segmental Glomerulosclerosis: A Review of Proposed Candidates. Biomed Res Int (2016) 0.82
A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues. Clin Kidney J (2015) 0.81
Shp2 Associates with and Enhances Nephrin Tyrosine Phosphorylation and Is Necessary for Foot Process Spreading in Mouse Models of Podocyte Injury. Mol Cell Biol (2015) 0.81
Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease. Case Rep Nephrol (2016) 0.81
Issues in solid-organ transplantation in children: translational research from bench to bedside. Clinics (Sao Paulo) (2014) 0.81
Genome sequencing in microfabricated high-density picolitre reactors. Nature (2005) 150.21
The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 11.16
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol (2009) 9.67
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med (2007) 9.51
BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med (2003) 7.91
Hypoxia and inflammation. N Engl J Med (2011) 7.71
Gene prioritization through genomic data fusion. Nat Biotechnol (2006) 7.48
Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell (2011) 7.30
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Cell biology of the glomerular podocyte. Physiol Rev (2003) 6.85
A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol (2002) 6.48
Basic and therapeutic aspects of angiogenesis. Cell (2011) 6.40
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol (2002) 6.24
Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol (2008) 5.83
Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell (2010) 5.77
Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med (2013) 5.62
TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet (2005) 5.53
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50
Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem (2007) 5.37
Global diversity in the human salivary microbiome. Genome Res (2009) 5.16
Metabolite identification via the Madison Metabolomics Consortium Database. Nat Biotechnol (2008) 5.12
Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med (2002) 5.10
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell (2007) 5.09
The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med (2008) 5.01
Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med (2010) 4.88
Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med (2015) 4.85
Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest (2007) 4.80
Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest (2004) 4.65
Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA. Cell Res (2011) 4.55
Origin and function of myofibroblasts in kidney fibrosis. Nat Med (2013) 4.55
Functional screening identifies miRNAs inducing cardiac regeneration. Nature (2012) 4.39
Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol (2007) 4.31
Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther (2006) 4.20
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest (2008) 4.12
Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol (2011) 4.09
Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet (2008) 3.94
HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell (2011) 3.89
Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res (2007) 3.86
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol (2011) 3.83
The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature (2004) 3.77
Mouse models of diabetic nephropathy. J Am Soc Nephrol (2009) 3.74
Exchange-coupled nanocomposite magnets by nanoparticle self-assembly. Nature (2002) 3.71
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest (2002) 3.70
Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell (2003) 3.68
eRNAs are required for p53-dependent enhancer activity and gene transcription. Mol Cell (2012) 3.63
Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med (2010) 3.60
The histone H3K4 demethylase SMCX links REST target genes to X-linked mental retardation. Nature (2007) 3.55
A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc Natl Acad Sci U S A (2004) 3.48
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet (2007) 3.47
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer (2008) 3.46
VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev Dyn (2006) 3.38
Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem (2003) 3.36
The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med (Berl) (2004) 3.32
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci (2004) 3.31
Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat Cell Biol (2006) 3.31
Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell (2009) 3.27
A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature (2011) 3.25
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell (2012) 3.19
Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med (2011) 3.19
Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science (2013) 3.17
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17
Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int (2002) 3.16
Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet (2010) 3.15
Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell (2002) 3.11
VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature (2004) 3.08
Research capacity. Enabling the genomic revolution in Africa. Science (2014) 3.05
Role of PFKFB3-driven glycolysis in vessel sprouting. Cell (2013) 3.04
Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc Natl Acad Sci U S A (2006) 3.03
Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell (2011) 3.00
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol (2012) 2.92
Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol (2008) 2.91
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest (2011) 2.90
Validation of endogenous controls for gene expression analysis in microdissected human renal biopsies. Kidney Int (2003) 2.90
Endogenous inhibitors of angiogenesis. Cancer Res (2005) 2.88
Loss of β1-integrin from urothelium results in overactive bladder and incontinence in mice: a mechanosensory rather than structural phenotype. FASEB J (2013) 2.86
Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes (2006) 2.85